Latest news with #PatrickSoon-Shiong
Yahoo
3 days ago
- Business
- Yahoo
Why ImmunityBio, Inc. (IBRX) Skyrocketed Today
We recently published a list of . In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other Wednesday's best-performing stocks. ImmunityBio extended its winning streak to a fifth consecutive day on Wednesday, jumping 8.1 percent to finish at $2.93 apiece as investors cheered the Food and Drug Administration's (FDA) green light for the company to expand the access of its Anktiva treatment to patients with solid tumors. According to ImmunityBio, Inc. (NASDAQ:IBRX), it was granted by the FDA to treat lymphopenia in adult patients with refractory or relapsed solid tumors. 'Lymphopenia has long been recognized as a major driver and predictor of early mortality in cancer—yet until now, it has remained unaddressed,' said ImmunityBio, Inc. (NASDAQ:IBRX) founder and Executive Chairman Patrick Soon-Shiong. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. 'This FDA authorization allows all patients with solid tumors suffering from immune collapse following first-line therapy of chemo, radiation, or immunotherapy to access ANKTIVA. The survival benefit we observed at ASCO 2025 in 3rd to 6th line advanced metastatic pancreatic cancer confirms that restoring lymphocyte levels, rather than depleting them, can change the course of disease.' Following the announcement, the company earned a 'buy' recommendation and a price target of $8 from investment firm HC Wainwright. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Why ImmunityBio, Inc. (IBRX) Skyrocketed Today
We recently published a list of . In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other Wednesday's best-performing stocks. ImmunityBio extended its winning streak to a fifth consecutive day on Wednesday, jumping 8.1 percent to finish at $2.93 apiece as investors cheered the Food and Drug Administration's (FDA) green light for the company to expand the access of its Anktiva treatment to patients with solid tumors. According to ImmunityBio, Inc. (NASDAQ:IBRX), it was granted by the FDA to treat lymphopenia in adult patients with refractory or relapsed solid tumors. 'Lymphopenia has long been recognized as a major driver and predictor of early mortality in cancer—yet until now, it has remained unaddressed,' said ImmunityBio, Inc. (NASDAQ:IBRX) founder and Executive Chairman Patrick Soon-Shiong. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. 'This FDA authorization allows all patients with solid tumors suffering from immune collapse following first-line therapy of chemo, radiation, or immunotherapy to access ANKTIVA. The survival benefit we observed at ASCO 2025 in 3rd to 6th line advanced metastatic pancreatic cancer confirms that restoring lymphocyte levels, rather than depleting them, can change the course of disease.' Following the announcement, the company earned a 'buy' recommendation and a price target of $8 from investment firm HC Wainwright. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
FDA grants expanded access to ImmunityBio's Anktiva for lymphopenia
The US Food and Drug Administration (FDA) has granted expanded access authorisation for ImmunityBio's Cancer BioShield platform, anchored by Anktiva (nogapendekin alfa inbakicept-pmln), to treat lymphopenia in adults with refractory or relapsed solid tumours. The approval applies regardless of tumour type and is intended for those who have progressed after first-line standard-of-care treatments, including radiation, chemotherapy or immunotherapy. Lymphopenia refers to the depletion of critical lymphocytes that are responsible for immunogenic cell death. Treatment-induced lymphopenia can be a consequence of radiation therapy, chemotherapy and certain immunotherapies, as well as steroids. Anktiva is designed specifically to address Bacille Calmette-Guérin (BCG)-unresponsive bladder cancer through its mechanism as an interleukin-15 (IL-15) superagonist that proliferates key lymphocytes. As an IL-15 agonist, Anktiva becomes the first approved therapy with a defined mechanism aimed at restoring levels of the vital immune cells without inducing regulatory T cells, thus providing a solution to reverse this critical immune deficit among cancer patients. Recent results have indicated that reversing lymphopenia using both Anktiva and chimeric antigen receptor-natural killer therapy prolongs median overall survival rates among patients with third to sixth-line metastatic pancreatic cancer. Enhanced benefits were observed when treatment commenced at lower tumour burdens indicated by CA19-9 levels. ImmunityBio founder, executive chairman and global chief scientific and medical officer Dr Patrick Soon-Shiong stated: 'Lymphopenia has long been recognised as a major driver and predictor of early mortality in cancer — yet until now, it has remained unaddressed. 'This FDA authorisation allows all patients with solid tumours suffering from immune collapse following first-line therapy of chemo, radiation or immunotherapy to access Anktiva.' In February 2025, ImmunityBio announced the receipt of regenerative medicine advanced therapy designation from the FDA concerning both Anktiva and CAR-NK. "FDA grants expanded access to ImmunityBio's Anktiva for lymphopenia" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
FDA grants expanded access to ImmunityBio's Anktiva for lymphopenia
The US Food and Drug Administration (FDA) has granted expanded access authorisation for ImmunityBio's Cancer BioShield platform, anchored by Anktiva (nogapendekin alfa inbakicept-pmln), to treat lymphopenia in adults with refractory or relapsed solid tumours. The approval applies regardless of tumour type and is intended for those who have progressed after first-line standard-of-care treatments, including radiation, chemotherapy or immunotherapy. Lymphopenia refers to the depletion of critical lymphocytes that are responsible for immunogenic cell death. Treatment-induced lymphopenia can be a consequence of radiation therapy, chemotherapy and certain immunotherapies, as well as steroids. Anktiva is designed specifically to address Bacille Calmette-Guérin (BCG)-unresponsive bladder cancer through its mechanism as an interleukin-15 (IL-15) superagonist that proliferates key lymphocytes. As an IL-15 agonist, Anktiva becomes the first approved therapy with a defined mechanism aimed at restoring levels of the vital immune cells without inducing regulatory T cells, thus providing a solution to reverse this critical immune deficit among cancer patients. Recent results have indicated that reversing lymphopenia using both Anktiva and chimeric antigen receptor-natural killer therapy prolongs median overall survival rates among patients with third to sixth-line metastatic pancreatic cancer. Enhanced benefits were observed when treatment commenced at lower tumour burdens indicated by CA19-9 levels. ImmunityBio founder, executive chairman and global chief scientific and medical officer Dr Patrick Soon-Shiong stated: 'Lymphopenia has long been recognised as a major driver and predictor of early mortality in cancer — yet until now, it has remained unaddressed. 'This FDA authorisation allows all patients with solid tumours suffering from immune collapse following first-line therapy of chemo, radiation or immunotherapy to access Anktiva.' In February 2025, ImmunityBio announced the receipt of regenerative medicine advanced therapy designation from the FDA concerning both Anktiva and CAR-NK. "FDA grants expanded access to ImmunityBio's Anktiva for lymphopenia" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
27-05-2025
- Health
- Business Wire
AirStrip® Introduces Alarm Management: A Game-Changing FDA Approved Integrated Platform Transforming Clinical Alarm Management of Vital Signs
SAN ANTONIO, Texas--(BUSINESS WIRE)-- AirStrip, a leader in vendor-agnostic clinical surveillance and decision support technologies, today announced the launch of AirStrip Alarm Management, an advanced integrated platform that modernizes how hospitals manage clinical alarms. This state-of-the-art, FDA approved solution routes critical alerts directly to clinicians' mobile devices, supported by waveform vital sign data, helping care teams respond faster and reduce alarm fatigue across care settings. Built to integrate seamlessly with existing systems, AirStrip Alarm Management supports a unified, vendor-neutral approach to alarm workflows. The MDI library enables hospitals to access data from disparate devices and systems, enhancing visibility and decision-making. Dr. Patrick Soon-Shiong, Chairman of AirStrip's Board of Directors, said, "This FDA approved platform is a meaningful advancement for healthcare systems. It simplifies alarm management, eases clinician workload, and contributes to a safer, more sustainable care environment especially for high risk, high cost patient care." With support from AirStrip, hospitals can custom-select configurations for alert escalations and notifications. This platform integrates with staff assignment solutions to avoid over-alerting while supporting unit-specific overrides, delivering clinically actionable alerts. Our centralized dashboard allows end users to dispatch alerts, document significant arrhythmias to the EHR, and track alarms in near-real time, offering automated audit trails for workflow transparency. Clinicians receive alerts enriched with contextual information and waveforms, allowing them to act immediately or escalate when necessary. The Alert Tracker feature gives hospital leaders insight into alarm activity across the system with near real-time updates and detailed logs. Dr. Haris Naseem, AirStrip's CEO and a practicing cardiac electrophysiologist, noted, "As someone who experiences alarm fatigue firsthand, I see the immediate clinical value of this solution. It brings clarity to urgent situations and helps us deliver faster, safer care." Since 2015, AirStrip has delivered innovative clinical surveillance solutions to hospitals nationwide. Following its acquisition of DECISIO® Health, the company has expanded its portfolio to include robust clinical decision support and visualization tools. The launch of AirStrip Alarm Management marks the next step in its mission to improve patient care, enhance clinical workflows, and support hospital staff at every level. AirStrip® is a leader in clinical surveillance, decision support, and alarm management solutions. Trusted by more than 675 hospitals and health systems across the United States, FDA approved software by AirStrip empowers clinicians to deliver timely, data-driven care with actionable insights at the point of care. Learn more at
